JA WP5 - Relative Effectiveness Assessment of Pharmaceuticals
- To develop principles, methodological guidance as well as functional online tools and policies for REA by identifying areas where methodological guidance is needed and by providing it, suggesting ways to integrate REA of pharmaceuticals as a special version of the Core Model
- To test and implement a REA group of pharmaceuticals in line with the core HTA development.
- A methodological guidance that will be appropiate for the assessment of relative effectiveness of pharmaceuticals
- A relative effectiveness assessment of a (group) of pharmaceutical(s)
AOTMiT, AIFA, ESKI, Hungary, GOEG, Austria, HIQA, HVB, INFARMED, IQWIG, KCE, MoH Czech, NICE, NIPHNO (formerly NOKC), SDU, SSD/MSOC, Malta, THL, VEC, Latvia